Cellectis S.A. (CLLS) income statement
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.92−0.06 (-6.39%)
Close on Nov 20, 2026Market cap $92.40MP/E –Yield –
Cellectis S.A. financial ratios
See a number that looks wrong?